Review Article | Published:

Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease

Nature Reviews Neuroscience volume 18, pages 419434 (2017) | Download Citation

Abstract

Cerebral blood flow (CBF) regulation is essential for normal brain function. The mammalian brain has evolved a unique mechanism for CBF control known as neurovascular coupling. This mechanism ensures a rapid increase in the rate of CBF and oxygen delivery to activated brain structures. The neurovascular unit is composed of astrocytes, mural vascular smooth muscle cells and pericytes, and endothelia, and regulates neurovascular coupling. This Review article examines the cellular and molecular mechanisms within the neurovascular unit that contribute to CBF control, and neurovascular dysfunction in neurodegenerative disorders such as Alzheimer disease.

Key points

  • Here, we review literature determining the arterial and arteriolar component of cerebral blood flow regulation.

  • Furthermore, we describe evidence of arterial and arteriolar blood flow control by vascular smooth muscle cells (VSMCs), astrocyte-mediated, direct neuron-mediated and endothelium-mediated regulation of VSMC tone.

  • Also, we discuss the capillary component of cerebral blood flow regulation.

  • Importantly, we highlight recent findings regarding the control of capillary blood flow by pericytes, and signalling in astrocytes and pericytes regulating capillary tone.

  • In addition, we examine vascular dysfunction in animal models, including amyloid-β-independent vascular changes, amyloid-β-dependent vascular changes and combined amyloid-β and vascular models.

  • Last, we emphasize Alzheimer disease vascular dysfunction, including cerebrovascular reactivity, cerebral blood flow reductions and neurovascular uncoupling.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 12, 723–738 (2011).

  2. 2.

    et al. Glial and neuronal control of brain blood flow. Nature 468, 232–243 (2010).

  3. 3.

    The pathobiology of vascular dementia. Neuron 80, 844–866 (2013).

  4. 4.

    , & The science of stroke: mechanisms in search of treatments. Neuron 67, 181–198 (2010).

  5. 5.

    Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5, 347–360 (2004).

  6. 6.

    Interpreting oxygenation-based neuroimaging signals: the importance and the challenge of understanding brain oxygen metabolism. Front. Neuroenergetics 2, 8 (2010).

  7. 7.

    , , , & Nonlinear coupling between cerebral blood flow, oxygen consumption, and ATP production in human visual cortex. Proc. Natl Acad. Sci. USA 107, 8446–8451 (2010).

  8. 8.

    , , & Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc. Natl Acad. Sci. USA 100, 253–258 (2003).

  9. 9.

    & A brief history of the resting state: the Washington University perspective. Neuroimage 62, 902–910 (2012).

  10. 10.

    & The neural basis of functional brain imaging signals. Trends Neurosci. 25, 621–625 (2002).

  11. 11.

    , , & Neuronal inhibition and excitation, and the dichotomic control of brain hemodynamic and oxygen responses. Neuroimage 62, 1040–1050 (2012).

  12. 12.

    Coupling mechanism and significance of the BOLD signal: a status report. Annu. Rev. Neurosci. 37, 161–181 (2014).

  13. 13.

    & Revisiting the role of neurons in neurovascular coupling. Front. Neuroenergetics 2, 9 (2010).

  14. 14.

    & Glial regulation of the cerebral microvasculature. Nat. Neurosci. 10, 1369–1376 (2007).

  15. 15.

    , , & Establishment and dysfunction of the blood–brain barrier. Cell 163, 1064–1078 (2015).

  16. 16.

    , , , & High-speed vascular dynamics of the hemodynamic response. Neuroimage 54, 1021–1030 (2011).

  17. 17.

    , , , & Critical role for the vascular endothelium in functional neurovascular coupling in the brain. J. Am. Heart Assoc. 3, e000787 (2014).

  18. 18.

    , , & Local and propagated vascular responses evoked by focal synaptic activity in cerebellar cortex. J. Neurophysiol. 78, 651–659 (1997).

  19. 19.

    et al. Cortical depth-specific microvascular dilation underlies laminar differences in blood oxygenation level-dependent functional MRI signal. Proc. Natl Acad. Sci. USA 107, 15246–15251 (2010).

  20. 20.

    et al. 'Overshoot' of O2 is required to maintain baseline tissue oxygenation at locations distal to blood vessels. J. Neurosci. 31, 13676–13681 (2011).

  21. 21.

    et al. Two-photon NADH imaging exposes boundaries of oxygen diffusion in cortical vascular supply regions. J. Cereb. Blood Flow Metab. 31, 68–81 (2011).

  22. 22.

    et al. Large arteriolar component of oxygen delivery implies a safe margin of oxygen supply to cerebral tissue. Nat. Commun. 5, 5734 (2014).

  23. 23.

    et al. Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain. Nat. Neurosci. 20, 406–416 (2017). This was the first study to demonstrate that pericyte degeneration in a pericyte loss-of-function model leads to a loss of neurovascular coupling and diminished O2 delivery to brain.

  24. 24.

    et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature 508, 55–60 (2014). This was the first study to show that pericytes have an active role in CBF regulation in vivo and that capillaries can dilate ahead of arterioles. In ischaemic conditions, pericytes rapidly constrict capillaries and die, consistent with the no-reflow phenomenon observed in stroke.

  25. 25.

    et al. Regional blood flow in the normal and ischemic brain is controlled by arteriolar smooth muscle cell contractility and not by capillary pericytes. Neuron 87, 95–110 (2015).

  26. 26.

    et al. Astrocytes mediate neurovascular signaling to capillary pericytes but not to arterioles. Nat. Neurosci. 19, 1619–1627 (2016). This was the first study to show that astrocytes mediate neurovascular signalling to capillary pericytes but not to arterioles, which involves a rise of Ca2+ in astrocytes caused by entry through adenosine triphosphate-gated channels.

  27. 27.

    et al. Glial cell calcium signaling mediates capillary regulation of blood flow in the retina. J. Neurosci. 36, 9435–9445 (2016).

  28. 28.

    & Diversity of astrocyte functions and phenotypes in neural circuits. Nat. Neurosci. 18, 942–952 (2015).

  29. 29.

    et al. Regional astrocyte allocation regulates CNS synaptogenesis and repair. Science 337, 358–362 (2012).

  30. 30.

    , & Neuroglial transmission. Physiol. Rev. 95, 695–726 (2015).

  31. 31.

    et al. Astrocytes contribute to gamma oscillations and recognition memory. Proc. Natl Acad. Sci. USA 111, E3343–E3352 (2014).

  32. 32.

    Astrocyte barriers to neurotoxic inflammation. Nat. Rev. Neurosci. 16, 249–263 (2015).

  33. 33.

    & Calcium transients in astrocyte endfeet cause cerebrovascular constrictions. Nature 431, 195–199 (2004).

  34. 34.

    et al. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat. Neurosci. 6, 43–50 (2003).

  35. 35.

    et al. Astrocyte-mediated control of cerebral blood flow. Nat. Neurosci. 9, 260–267 (2006).

  36. 36.

    & Astrocyte regulation of blood flow in the brain. Cold Spring Harb. Perspect. Biol. 7, a020388 (2015).

  37. 37.

    et al. Calcium dynamics in astrocyte processes during neurovascular coupling. Nat. Neurosci. 18, 210–218 (2015).

  38. 38.

    et al. What is the role of astrocyte calcium in neurophysiology? Neuron 59, 932–946 (2008).

  39. 39.

    et al. In vivo stimulus-induced vasodilation occurs without IP3 receptor activation and may precede astrocytic calcium increase. J. Neurosci. 33, 8411–8422 (2013).

  40. 40.

    & Astrocytic Gq-GPCR-linked IP3R-dependent Ca2+ signaling does not mediate neurovascular coupling in mouse visual cortex in vivo. J. Neurosci. 34, 13139–13150 (2014).

  41. 41.

    et al. Glutamate-dependent neuroglial calcium signaling differs between young and adult brain. Science 339, 197–200 (2013).

  42. 42.

    & Glutamatergic and purinergic receptor-mediated calcium transients in Bergmann glial cells. J. Neurosci. 27, 4027–4035 (2007).

  43. 43.

    et al. Astrocyte contributions to flow/pressure-evoked parenchymal arteriole vasoconstriction. J. Neurosci. 35, 8245–8257 (2015).

  44. 44.

    , , & TRPV4 channels stimulate Ca2+-induced Ca2+ release in astrocytic endfeet and amplify neurovascular coupling responses. Proc. Natl Acad. Sci. USA 110, 6157–6162 (2013).

  45. 45.

    & Vascular inward rectifier K+ channels as external K+ sensors in the control of cerebral blood flow. Microcirculation 22, 183–196 (2015).

  46. 46.

    et al. Astrocytic endfoot Ca2+ and BK channels determine both arteriolar dilation and constriction. Proc. Natl Acad. Sci. USA 107, 3811–3816 (2010).

  47. 47.

    , , , & Brain metabolism dictates the polarity of astrocyte control over arterioles. Nature 456, 745–749 (2008). This study in live brain slices revealed that the metabolic state of brain tissue, such as oxygenation and lactate levels, influences both arteriolar dilation or constriction.

  48. 48.

    , & Oxygen modulation of neurovascular coupling in the retina. Proc. Natl Acad. Sci. USA 108, 17827–17831 (2011).

  49. 49.

    , , & Microinjection of L-lactate in the preretinal vitreous induces segmental vasodilation in the inner retina of miniature pigs. Invest. Ophthalmol. Vis. Sci. 34, 1744–1752 (1993).

  50. 50.

    , & Lactate dilates cochlear capillaries via type V fibrocyte-vessel coupling signaled by nNOS. Am. J. Physiol. Heart Circ. Physiol. 301, H1248–H1254 (2011).

  51. 51.

    & Nitric oxide mediates vasodilatation in response to activation of N-methyl-D-aspartate receptors in brain. Circ. Res. 72, 476–480 (1993). This classic paper demonstrated that activation of N-methyl-d-aspartate receptors in neurons leads to concentration-dependent NO-mediated dilation of pial arterioles.

  52. 52.

    et al. P-450 epoxygenase and NO synthase inhibitors reduce cerebral blood flow response to N-methyl-D-aspartate. Am. J. Physiol. Heart Circ. Physiol. 279, H1616–H1624 (2000).

  53. 53.

    , , & Temporal dynamics of brain tissue nitric oxide during functional forepaw stimulation in rats. Neuroimage 18, 1–9 (2003).

  54. 54.

    & Purinergic control of vascular tone in the retina. J. Physiol. 592, 491–504 (2014).

  55. 55.

    , , & Analysis of purine- and pyrimidine-induced vascular responses in the isolated rat cerebral arteriole. Am. J. Physiol. Heart Circ. Physiol. 280, H767–H776 (2001).

  56. 56.

    & Purinergic signalling in neuron–glia interactions. Nat. Rev. Neurosci. 7, 423–436 (2006).

  57. 57.

    et al. Astrocytic purinergic signaling coordinates synaptic networks. Science 310, 113–116 (2005).

  58. 58.

    et al. Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity. Proc. Natl Acad. Sci. USA 109, 6265–6270 (2012).

  59. 59.

    , & The locus coeruleus-norepinephrine network optimizes coupling of cerebral blood volume with oxygen demand. J. Cereb. Blood Flow Metab. 32, 2135–2145 (2012).

  60. 60.

    , , , & Resolving the transition from negative to positive blood oxygen level-dependent responses in the developing brain. Proc. Natl Acad. Sci. USA 110, 4380–4385 (2013).

  61. 61.

    et al. Cell type specificity of neurovascular coupling in cerebral cortex. eLife 5, e14315 (2016).

  62. 62.

    et al. Non-linear relationship between hyperpolarisation and relaxation enables long distance propagation of vasodilatation. J. Physiol. 589, 2607–2623 (2011).

  63. 63.

    & Purinergic transmission in blood vessels. Auton. Neurosci. 191, 48–66 (2015).

  64. 64.

    , , , & Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain. J. Neurochem. 115, 1077–1089 (2010).

  65. 65.

    , , , & What is a pericyte? J. Cereb. Blood Flow Metab. 36, 451–455 (2016).

  66. 66.

    & Diverse functions of pericytes in cerebral blood flow regulation and ischemia. J. Cereb. Blood Flow Metab. 35, 883–887 (2015).

  67. 67.

    et al. Pericyte structure and distribution in the cerebral cortex revealed by high-resolution imaging of transgenic mice. Neurophotonics 2, 041402 (2015).

  68. 68.

    et al. Pericyte endothelial gap junctions in human cerebral capillaries. Anat. Embryol. (Berl.) 170, 155–159 (1984).

  69. 69.

    , & Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 21, 193–215 (2011).

  70. 70.

    , & N-Cadherin mediates pericytic-endothelial interaction during brain angiogenesis in the chicken. Dev. Dyn. 218, 472–479 (2000).

  71. 71.

    , & Central nervous system pericytes in health and disease. Nat. Neurosci. 14, 1398–1405 (2011).

  72. 72.

    et al. Brain structure. Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. Science 347, 1138–1142 (2015).

  73. 73.

    , & Pericytes of the neurovascular unit: key functions and signaling pathways. Nat. Neurosci. 19, 771–783 (2016).

  74. 74.

    , , & Visualization and contractile activity of cochlear pericytes in the capillaries of the spiral ligament. Hear. Res. 254, 100–107 (2009).

  75. 75.

    , , , & Pericytes in capillaries are contractile in vivo, but arterioles mediate functional hyperemia in the mouse brain. Proc. Natl Acad. Sci. USA 107, 22290–22295 (2010).

  76. 76.

    , , & Novel method to study pericyte contractility and responses to ischaemia in vitro using electrical impedance. J. Cereb. Blood Flow Metab. (2016).

  77. 77.

    , , & Bidirectional control of CNS capillary diameter by pericytes. Nature 443, 700–704 (2006). This important work in brain slices and retina demonstrated pericyte contractility and control of capillary diameter.

  78. 78.

    , , & Extracellular lactate as a dynamic vasoactive signal in the rat retinal microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290, H925–H934 (2006).

  79. 79.

    et al. Erythrocytes are oxygen-sensing regulators of the cerebral microcirculation. Neuron 91, 851–862 (2016).

  80. 80.

    et al. Effects of angiotensin II on the pericyte-containing microvasculature of the rat retina. J. Physiol. 561, 671–683 (2004).

  81. 81.

    et al. Contractile proteins in pericytes at the blood–brain and blood–retinal barriers. J. Neurocytol. 30, 35–44 (2001).

  82. 82.

    , , & Two-photon imaging of capillary blood flow in olfactory bulb glomeruli. Proc. Natl Acad. Sci. USA 100, 13081–13086 (2003).

  83. 83.

    et al. Functional reactivity of cerebral capillaries. J. Cereb. Blood Flow Metab. 28, 961–972 (2008).

  84. 84.

    , , & Spatial flow-volume dissociation of the cerebral microcirculatory response to mild hypercapnia. Neuroimage 32, 520–530 (2006).

  85. 85.

    et al. Early loss of pericytes and perivascular stromal cell-induced scar formation after stroke. J. Cereb. Blood Flow Metab. 33, 428–439 (2013).

  86. 86.

    et al. Pericyte contraction induced by oxidative–nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat. Med. 15, 1031–1037 (2009).

  87. 87.

    et al. ATP: a vasoactive signal in the pericyte-containing microvasculature of the rat retina. J. Physiol. 551, 787–799 (2003).

  88. 88.

    , , , & S phase entry of neural progenitor cells correlates with increased blood flow in the young subventricular zone. PLoS ONE 7, e31960 (2012).

  89. 89.

    , & Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease. Front. Neuroenergetics 2, 5 (2010).

  90. 90.

    et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol. Commun. 1, 65 (2013).

  91. 91.

    et al. Blood–brain barrier breakdown in the aging human hippocampus. Neuron 85, 296–302 (2015). This study was the first to demonstrate age-associated BBB breakdown in the hippocampus in the living human brain and accelerated breakdown in humans with MCI.

  92. 92.

    , & Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease. J. Cereb. Blood Flow Metab. 35, 1055–1068 (2015).

  93. 93.

    , , , & Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study. Lancet Neurol. 15, 934–943 (2016). This large cross-sectional neuropathological study showed that cerebral vessel disease plays a part in dementia that is typically attributed to AD during life.

  94. 94.

    , , , & Alzheimer's Disease Neuroimaging Initiative. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat. Commun. 7, 11934 (2016). This was one of the largest and most comprehensive biomarker studies to show the early role of vascular dysregulation in memory dysfunction in AD prior to cerebral amyloidosis and tau-mediated neurodegeneration.

  95. 95.

    , , & Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease. Biochim. Biophys. Acta 1862, 887–900 (2016).

  96. 96.

    et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 12, 822–838 (2013).

  97. 97.

    et al. ADRD 2013 Conference Organizing Committee. Recommendations of the Alzheimer's disease-related dementias conference. Neurology 83, 851–860 (2014).

  98. 98.

    et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement. 11, 710–717 (2015).

  99. 99.

    World Stroke Organization. Stroke and potentially preventable dementias proclamation: updated World Stroke Day proclamation. Stroke 46, 3039–3040 (2015).

  100. 100.

    Cerebrovascular effects of amyloid-ß peptides: mechanisms and implications for Alzheimer's dementia. Cell. Mol. Neurobiol. 23, 681–689 (2003).

  101. 101.

    The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178–201 (2008).

  102. 102.

    et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68, 409–427 (2010).

  103. 103.

    et al. Deficiency in mural vascular cells coincides with blood–brain barrier disruption in Alzheimer's disease. Brain Pathol. 23, 303–310 (2013).

  104. 104.

    et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J. Cereb. Blood Flow Metab. 36, 216–227 (2015).

  105. 105.

    et al. Age-dependent neurovascular dysfunction and damage in a mouse model of cerebral amyloid angiopathy. Stroke 45, 1815–1821 (2014).

  106. 106.

    et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat. Commun. 4, 2932 (2013).

  107. 107.

    & Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64, 575–611 (2001).

  108. 108.

    & The vascular factor in Alzheimer's disease: a study in Golgi technique and electron microscopy. J. Neurol. Sci. 322, 117–121 (2012).

  109. 109.

    et al. Blood–spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol. 125, 111–120 (2013).

  110. 110.

    , , , & Blood–spinal cord barrier pericyte reductions contribute to increased capillary permeability. J. Cereb. Blood Flow Metab. 32, 1841–1852 (2012).

  111. 111.

    et al. Pericytes as inducers of rapid, matrix metalloproteinase-9-dependent capillary damage during ischemia. J. Neurosci. 37, 129–140 (2017).

  112. 112.

    et al. Lipoprotein receptor-related protein-1 mediates amyloid-ß-mediated cell death of cerebrovascular cells. Am. J. Pathol. 171, 1989–1999 (2007).

  113. 113.

    & Hypertension: a harbinger of stroke and dementia. Hypertension 62, 810–817 (2013).

  114. 114.

    et al. Central cardiovascular circuits contribute to the neurovascular dysfunction in angiotensin II hypertension. J. Neurosci. 32, 4878–4886 (2012).

  115. 115.

    et al. Hypertension enhances Aβ-induced neurovascular dysfunction, promotes β-secretase activity, and leads to amyloidogenic processing of APP. J. Cereb. Blood Flow Metab. 36, 241–252 (2016).

  116. 116.

    et al. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am. J. Physiol. Heart Circ. Physiol. 300, H397–H407 (2011).

  117. 117.

    Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ. Res. 95, 1019–1026 (2004).

  118. 118.

    Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through Nox-2-derived radicals. Arterioscler. Thromb. Vasc. Biol. 26, 826–832 (2006).

  119. 119.

    , , & Impaired endothelial function in transgenic mice expressing both human renin and human angiotensinogen. Stroke 31, 760–765 (2000).

  120. 120.

    et al. Age-related autoregulatory dysfunction and cerebromicrovascular injury in mice with angiotensin II-induced hypertension. J. Cereb. Blood Flow Metab. 33, 1732–1742 (2013).

  121. 121.

    et al. Pericytes are involved in the pathogenesis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Ann. Neurol. 78, 887–900 (2015).

  122. 122.

    et al. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J. Clin. Invest. 120, 433–445 (2010).

  123. 123.

    & Pericytes as a new target for pathological processes in CADASIL. Neuropathology 32, 515–521 (2012).

  124. 124.

    , , , & Impaired cerebral vasoreactivity in a transgenic mouse model of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy arteriopathy. Stroke 36, 1053–1058 (2005).

  125. 125.

    et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512–516 (2012).

  126. 126.

    et al. A dietary treatment improves cerebral blood flow and brain connectivity in aging apoE4 mice. Neural Plast. 2016, 6846721 (2016).

  127. 127.

    , , , & Human apolipoprotein E ɛ4 expression impairs cerebral vascularization and blood–brain barrier function in mice. J. Cereb. Blood Flow Metab. 35, 86–94 (2015).

  128. 128.

    , , , & β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168–171 (1996). This paper was the first to demonstrate Aβ vasoconstrictive properties in the isolated rat aorta.

  129. 129.

    , , , & Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein. J. Neurosci. 17, 7655–7661 (1997). This study was the first to demonstrate Aβ vasoactive properties on cerebral blood vessels in vivo in transgenic mice overexpressing APP (Swedish mutation).

  130. 130.

    et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2, 157–161 (1999).

  131. 131.

    et al. Aβ1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl Acad. Sci. USA 97, 9735–9740 (2000). This paper was the first to demonstrate altered neurovascular coupling by Aβ.

  132. 132.

    et al. RAGE mediates amyloid-ß peptide transport across the blood–brain barrier and accumulation in brain. Nat. Med. 9, 907–913 (2003).

  133. 133.

    et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Invest. 122, 1377–1392 (2012).

  134. 134.

    et al. NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid ß peptide. J. Neurosci. 25, 1769–1777 (2005).

  135. 135.

    et al. The key role of transient receptor potential melastatin-2 channels in amyloid-β-induced neurovascular dysfunction. Nat. Commun. 5, 5318 (2014).

  136. 136.

    et al. Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-ß. Proc. Natl Acad. Sci. USA 108, 5063–5068 (2011).

  137. 137.

    et al. SRF and myocardin regulate LRP-mediated amyloid-ß clearance in brain vascular cells. Nat. Cell Biol. 11, 143–153 (2009).

  138. 138.

    , , & Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease. Brain 138, 3716–3733 (2015).

  139. 139.

    et al. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc. Natl Acad. Sci. USA 104, 823–828 (2007).

  140. 140.

    et al. Angiotensin II, hypertension, and angiotensin II receptor antagonism: roles in the behavioural and brain pathology of a mouse model of Alzheimer's disease. J. Cereb. Blood Flow Metab. (2016).

  141. 141.

    et al. Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol. 123, 381–394 (2012).

  142. 142.

    et al. Cerebral amyloid angiopathy increases susceptibility to infarction after focal cerebral ischemia in Tg2576 mice. Stroke 45, 3064–3069 (2014).

  143. 143.

    & Hyperhomocysteinemia impairs regional blood flow: involvements of endothelial and neuronal nitric oxide. Pflugers Arch. 468, 1517–1525 (2016).

  144. 144.

    , , , & Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation. J. Cereb. Blood Flow Metab. 33, 708–715 (2013).

  145. 145.

    , , , & β-Amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice. Alzheimers Res. Ther. 6, 32 (2014).

  146. 146.

    , , & Impaired cerebral autoregulation and vasomotor reactivity in sporadic Alzheimer's disease. Curr. Alzheimer Res. 11, 11–17 (2014).

  147. 147.

    et al. Reduced cerebrovascular reactivity in young adults carrying the APOE ɛ4 allele. Alzheimers Dement. 11, 648–657.e1 (2015).

  148. 148.

    , & Apolipoprotein E, carbon dioxide vasoreactivity, and cognition in older adults: effect of hypertension. J. Am. Geriatr. Soc. 63, 276–281 (2015).

  149. 149.

    et al. Forebrain-dominant deficit in cerebrovascular reactivity in Alzheimer's disease. Neurobiol. Aging 33, 75–82 (2012).

  150. 150.

    et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann. Neurol. 57, 789–794 (2005). This large population-based study showed that diminished CBF precedes cognitive decline and hippocampal atrophy.

  151. 151.

    et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J. Nucl. Med. 41, 1155–1162 (2000).

  152. 152.

    et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42, 85–94 (1997).

  153. 153.

    et al. Functional interactions between entorhinal cortex and posterior cingulate cortex at the very early stage of Alzheimer's disease using brain perfusion single-photon emission computed tomography. Nucl. Med. Commun. 27, 151–156 (2006).

  154. 154.

    et al. Differential effects of APOE genotypes on the anterior and posterior subnetworks of default mode network in amnestic mild cognitive impairment. J. Alzheimers Dis. 54, 1409–1423 (2016).

  155. 155.

    et al. Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer's disease. J. Nucl. Med. 43, 304–311 (2002).

  156. 156.

    Cerebral hypoperfusion and glucose hypometabolism: key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease. J. Neurosci. Res. 95, 943–972 (2016).

  157. 157.

    et al. Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease. J. Nucl. Med. 45, 382–392 (2004).

  158. 158.

    et al. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 28, 1014–1021 (2005).

  159. 159.

    et al. Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiol. Aging 27, 24–31 (2006).

  160. 160.

    , , , & APOE ɛ4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch. Neurol. 67, 93–98 (2010).

  161. 161.

    et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl Acad. Sci. USA 101, 284–289 (2004).

  162. 162.

    et al. Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology 77, 1977–1985 (2011).

  163. 163.

    et al. Arterial spin labeling imaging reveals widespread and Aβ-independent reductions in cerebral blood flow in elderly apolipoprotein epsilon-4 carriers. J. Cereb. Blood Flow Metab. 36, 581–595 (2016).

  164. 164.

    et al. Divergent regional patterns of cerebral hypoperfusion and gray matter atrophy in mild cognitive impairment patients. J. Cereb. Blood Flow Metab. 37, 814–824 (2016).

  165. 165.

    , , , & Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann. Neurol. 45, 466–472 (1999).

  166. 166.

    et al. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74, 44–50 (2003).

  167. 167.

    et al. Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology 53, 1391–1396 (1999).

  168. 168.

    et al. Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy. Ann. Neurol. 72, 76–81 (2012).

  169. 169.

    & Biophysical and physiological origins of blood oxygenation level-dependent fMRI signals. J. Cereb. Blood Flow Metab. 32, 1188–1206 (2012).

  170. 170.

    & Functional brain connectivity using fMRI in aging and Alzheimer's disease. Neuropsychol. Rev. 24, 49–62 (2014).

  171. 171.

    et al. A default mode of brain function. Proc. Natl Acad. Sci. USA 98, 676–682 (2001).

  172. 172.

    , , & Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc. Natl Acad. Sci. USA 101, 4637–4642 (2004).

  173. 173.

    et al. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage 31, 496–504 (2006).

  174. 174.

    et al. Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology 81, 736–744 (2013).

  175. 175.

    et al. Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA Neurol. 71, 1111–1122 (2014).

  176. 176.

    et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J. Neurosci. 30, 17035–17040 (2010).

  177. 177.

    Der feinere Bau der Blutkapillaren [German]. Z. Anat. Entwicklungsgesch. 68, 29–110 (1923).

  178. 178.

    , & The pericyte: a forgotten cell type with important implications for Alzheimer's disease? Brain Pathol. 24, 371–386 (2014).

  179. 179.

    & Heterogeneity of microvascular pericytes for smooth muscle type alpha-actin. J. Cell Biol. 113, 147–154 (1991).

  180. 180.

    et al. Brain imaging of neurovascular dysfunction in Alzheimer's disease. Acta Neuropathol. 131, 687–707 (2016).

  181. 181.

    , , , & Blood–brain barrier permeability in Alzheimer's disease: a case-control MRI study. Psychiatry Res. 171, 232–241 (2009).

  182. 182.

    et al. Blood–brain barrier leakage in patients with early Alzheimer disease. Radiology 281, 527–535 (2016).

  183. 183.

    et al. Blood–brain barrier permeability abnormalities in vascular cognitive impairment. Stroke 42, 2158–2163 (2011).

  184. 184.

    et al. Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging. Neuroimage Clin. 3, 180–195 (2013).

Download references

Acknowledgements

The work of B.V.Z. is supported by the US National Institutes of Health (grants R01AG023084, R01NS090904, R01NS034467, R01AG039452, R01NS100459, P01AG052350) and Cure for Alzheimer's fund. The authors thank M. Sweeney for careful reading of the manuscript.

Author information

Author notes

    • Kassandra Kisler
    • , Amy R. Nelson
    •  & Axel Montagne

    These authors contributed equally to this work.

Affiliations

  1. Zilkha Neurogenetic Institute, 1501 San Pablo Street, Los Angeles, California 90089, USA.

    • Kassandra Kisler
    • , Amy R. Nelson
    • , Axel Montagne
    •  & Berislav V. Zlokovic

Authors

  1. Search for Kassandra Kisler in:

  2. Search for Amy R. Nelson in:

  3. Search for Axel Montagne in:

  4. Search for Berislav V. Zlokovic in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Berislav V. Zlokovic.

Glossary

Neurovascular coupling

The dynamic functional change in cerebral blood flow that occurs in response to local neuronal activity.

Functional hyperaemia

The increase in cerebral blood flow that occurs in response to brain activity.

Neurovascular unit

(NVU). A functionally integrated group of different cell types in the brain composed of vascular cells (endothelial cells, vascular smooth muscle cells and pericytes), glia (astrocytes, microglia and oligodendrocytes) and neurons.

Functional connectivity

The temporal dependency of neuronal activation patterns of anatomically separated brain regions determined by measuring the level of co-activation of resting-state MRI time series between brain regions.

Cytochrome P450

Enzymes belonging to a superfamily of haemoproteins that contain haem as a cofactor.

Cyclooxygenase 1

(COX1). An enzyme, also known as prostaglandin-endoperoxide synthase 1, responsible for the formation of prostanoids and prostaglandins.

Mechanical shear stress

The physical stress caused to endothelial cells by the flow of blood through vessels.

Hypercapnia

A condition of abnormally increased carbon dioxide levels in the blood.

Vasculotropic

Affecting, acting upon or attracted to blood vessels

Microhaemorrhages

Small focal cerebral microbleeds in the brain, which can be visualized by MRI sequences.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrn.2017.48

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing